• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors

ASCO Presentations Showcase Utility of Caris Molecular Intelligence in Cataloging Disease Biomarkers in Gastrointestinal, Hepatic, Gynecologic and Renal Cancer Subtypes


News provided by

Caris Life Sciences

May 29, 2015, 08:00 ET

Share this article

Share this article


IRVING, Texas, May 29, 2015 /PRNewswire/ -- Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors. In each of the studies, results of which are to be presented in poster sessions at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., multi-platform tumor profiling via Caris Molecular Intelligence enabled cataloging of biomarkers as potential therapeutic targets in various subtypes of gastrointestinal, hepatic, gynecologic and renal cancers.

Caris Molecular Intelligence is a multi-platform tumor profiling service that includes gene sequencing (Next-Generation Sequencing [NGS] and Sanger), protein expression analysis (Immunohistochemistry [IHC]), and gene copy number and translocation analysis (Chromogenic or Fluorescence in situ Hybridization [CISH or FISH]).  Investigators used these methods to examine tumor samples for patterns of biomarker expression that may yield insights into selection of novel therapeutic options for patients with rare and/or aggressive cancer subtypes.

"Although research advances have enhanced our understanding of rare and aggressive cancer subtypes, patients living with these malignancies have few therapeutic options," said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. "The latest cataloging analyses demonstrate that Caris Molecular Intelligence can facilitate the molecular characterization of these subtypes, as well as the identification and selection of treatment regimens that specifically target the biomarkers detected in individual patients' tumors."

Anal Squamous Cell Carcinoma Study
In a June 1 poster discussion (abstract # 33519), researchers described how Caris Molecular Intelligence was used to identify potential therapeutic targets based on detection and analysis of biomarkers in 212 cases of anal squamous cell carcinoma (ASCC), a rare, human papilloma virus (HPV)-associated malignancy that accounts for 2% of digestive system cancers. "Usually, anal squamous cell carcinomas are detected early and successfully managed with chemoradiation, but in some cases these cancers recur or present with metastases, a setting in which few endorsed regimens exist," explained lead investigator Patrick M. Boland, M.D., Assistant Professor of Oncology at the Roswell Park Cancer Center in Buffalo, N.Y. "With multi-platform molecular profiling, we identified several potential targets, some of which may be addressed with treatment options not routinely considered in this population."

Dr. Boland and colleagues reported overexpression of the MRP1 (97.6%), EGFR (89.7%), topoisomerase 1 (TOPO 1; 68.3%), and MGMT proteins (67.2%) in a majority of ASCC samples, as detected via IHC, which also documented overexpression of the tumor suppressor protein PTEN in 46.9% (90/192) of specimens. The ligand to the programmed cell death receptor 1 (PD-L1) was not expressed in any of the 24 samples examined via IHC. CISH/FISH analysis revealed amplification of the EGFR and HER2 genes in 7.4% (5/68) and 1.8% (2/111) of cases, respectively. The investigators observed relatively high mutation rates in biomarkers associated with the PIK3CA/Akt pathway; these included PIK3CA (26.8%, 26/97), FBXW7 (11.8%, 8/68), PTEN (3.1%, 2/64), and Akt1 (1.5%, 1/68). They detected PIK3CA exon 9 mutations in 82% of all PIK3CA mutations, while also identifying point mutations in other genes, including a few co-occurring mutations.

"Mutations in PIK3CA, Akt1, and FBXW7, along with PTEN loss, indicate a potential for targeting the PI3 kinase pathway in patients with anal squamous cell carcinoma," noted Dr. Boland. "Targeting the ErbB-family receptors, namely with anti-EGFR agents or newer-generation pan-HER inhibitors, may represent another option, given EGFR and HER2 amplification as well as EGFR overexpression.  Finally, differences in anal carcinomas whose etiology is of viral origin may present different treatment options based on the driver mutations. All of these molecular characteristics represent intriguing areas for future research."

Other ASCO Presentations in Rare/Aggressive Cancer Subtypes
The 2015 ASCO meeting features several other presentations in which researchers used Caris Molecular Intelligence to identify potential therapeutic targets in rare and/or aggressive cancer subtypes with limited treatment options:

  • Hepatocellular carcinoma (HCC) (Abstract #4086): A team of researchers led by Celina Ang, M.D., of Mount Sinai Hospital in New York concluded that multi-platform molecular profiling supports the previously reported molecular heterogeneity of HCC, based on an evaluation of 350 HCC samples. They identified tyrosine kinase inhibitors, anti-PD-1 agents and PI3 kinase inhibitors as potential targeted therapies for specific molecular subtypes. They also suggested immunomodulatory agents as a potential option, particularly in metastatic HCC, based on levels of PD-1. Concurrent protein changes in CTNNB1-mutated tumors suggest a potential benefit of combination therapies when targeting the Wnt pathway. The researchers added that review of responses to targeted therapies such as erlotinib, which is being investigated in a patient in their dataset whose tumor carries an EGFR mutation, may provide additional insight into efficacious therapies.
  • Small-cell cervical cancer (SCCC) (Abstract #5601): A team led by Michael M. Frumovitz, M.D., MPH, of The University of Texas MD Anderson Cancer Center identified prevalent targetable molecular aberrations in SCCC, an extremely rare and aggressive malignancy accounting for only 1% of cervical cancer cases, and which recurs in 70% of patients, even among those diagnosed with early-stage disease. Their analysis of 78 SCCC samples (including 53 via Caris Molecular Intelligence and 25 samples analyzed at a cancer center using a 50-gene NGS platform) identified high expression of TOPO2A and TOPO1, which may explain sensitivity to etoposide and topotecan, respectively. Potential druggable mutations in their analysis included Akt1, KRAS, PIK3CA and TP53. The researchers also identified one patient with a KRAS mutation who had a complete response to MEK inhibitor therapy and remains in remission at 12 months.
  • Mucinous epithelial ovarian carcinoma (mEOC) (Abstract #5540): Molecular profiling underscored the genomic heterogeneity and distinct molecular subsets in mEOCs, an uncommon subset of epithelial ovarian cancers that, when diagnosed in advanced stages, can be difficult to distinguish from gastrointestinal metastases to the ovary. Prof. Michael Friedlander, Ph.D., of Prince of Wales Hospital in Sydney, Australia, and colleagues used Caris Molecular Intelligence to evaluate 304 mEOCs. They identified numerous potential treatment targets, including alterations in the MAP kinase and mammalian target of rapamycin (mTOR) pathways, PD-1 positivity, cMET overexpression, and amplification of HER2 and EGFR, that could be investigated in Phase II basket trials, noting that such investigations would require international collaboration due to the rarity of advanced-stage mEOC.
  • Sarcomatoid renal cell carcinoma (sRCC) (Abstract #4556): Thai H. Ho, M.D., Ph.D. of the Mayo Clinic Cancer Center in Scottsdale, Ariz., and colleagues identified numerous predictive biomarkers for response to cytotoxic agents and immunotherapies in sRCC, a rare subset of renal cell carcinoma (RCC) characterized by poor prognosis and decreased likelihood of response to targeted therapy or interleukin-2 (IL-2) immunotherapy. Out of 112 RCC cases evaluated, 21 were categorized as sRCC and 91 as clear-cell RCC (ccRCC). The researchers observed frequent overexpression of TOPO2A and loss of RRM1 in the sRCC samples, noting that in other tumors, these markers are associated with sensitivity to anthracyclines and gemcitabine. They also observed increased infiltration of PD-1-positive tumor infiltrating lymphocytes (TILs) in the sRCC samples, suggestive of response to PD-1/PD-L1-targeted immunotherapies. Dr. Ho and colleagues concluded that further evaluation of TOPO2A, RRM1, and PD-1/PD-L1 as predictive biomarkers in sRCC is warranted.

About Caris Life Sciences®
Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient's tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris has tracked clinical and outcome data for certain patients undergoing tumor molecular profiling, for which Caris has observed that patients treated with drugs consistent with their molecular profile show a significant increase in overall survival. The company is developing its Carisome® TOP™ technology, a revolutionary and proprietary blood-based platform for the development of novel therapeutics, drug delivery and drug target identification. The technology is also being developed for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

SOURCE Caris Life Sciences

Related Links

http://www.CarisLifeSciences.com

Modal title

Also from this source

Caris Life Sciences Raises $400 Million in Senior Secured Debt

Caris Life Sciences Raises $400 Million in Senior Secured Debt


Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients

Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Biotechnology
  • Clinical Trials & Medical Discoveries
  • Trade Show News

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.